<p>The nonspecific human IgG1mAb, and the human and mouse anti-F1 and anti-V mAbs were given i.p. to mice 24 hrs before parenteral challenge with <i>Y. pestis</i> CO92, and the number of surviving mice for each treatment group was monitored for 21 days after challenge. Mouse or human mAbs and their amounts were given to the following groups of mice: nonspecific human IgG1 (Hu-IgG1, 1,500 µg); F1m (F1m, 500 µg); F1m (500 µg) + Hu-IgG1(1,000 µg); m252, 500 µg; m252 (500 µg) + Hu-IgG1 (1,000 µg).</p
Human intravenous immunoglobulin (IVIG) is a fractionated blood product that is used for the treatme...
For each model, mice were dosed with either 1μg α-OX40 antibody or 400μg isotype control antibody ev...
<p>Indicated treatments were given i.v. twice weekly when the tumors became palpable. (<b>a</b>) Com...
<p>The human anti-F1 m252 mAb was administered before or after <i>Y</i>. <i>pestis</i> challenge, an...
<p>The same amount of human IgGs (500 µg) as used in the challenge studies were administered via i.p...
<p>The human and mouse anti-F1 and anti-V mAbs were given i.p. to mice 24 hrs before parenteral chal...
<p>A mouse anti-<i>B mallei</i> IgG1was used (10 µg/ml) as an isotype mAb control, and the mouse ant...
a<p>Mice were treated i.p. with 100 µg of MAb at the indicated days before or after challenge with 1...
<p>Anti-H4 antibody (20 mg/ml) or the IgG control (20 mg/ml) were given once intravenously just befo...
a<p>Mice were treated i.p. with various doses of the MAb 1 dpi with 1000 LD<sub>50</sub> of the MA-Z...
Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized o...
Background: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly...
<p>(A) The Kaplan-Meier survival curve. BALB/c mice (n=7 per group in two separate experiments) were...
a<p><i>p</i> value vs. controls determined from Kaplan-Meier survival plots by log-rank (Mantel-Cox)...
<p>Mice were administered mAb(s) by the i.p. route followed 18 h later by i.n. challenge with 15 LD<...
Human intravenous immunoglobulin (IVIG) is a fractionated blood product that is used for the treatme...
For each model, mice were dosed with either 1μg α-OX40 antibody or 400μg isotype control antibody ev...
<p>Indicated treatments were given i.v. twice weekly when the tumors became palpable. (<b>a</b>) Com...
<p>The human anti-F1 m252 mAb was administered before or after <i>Y</i>. <i>pestis</i> challenge, an...
<p>The same amount of human IgGs (500 µg) as used in the challenge studies were administered via i.p...
<p>The human and mouse anti-F1 and anti-V mAbs were given i.p. to mice 24 hrs before parenteral chal...
<p>A mouse anti-<i>B mallei</i> IgG1was used (10 µg/ml) as an isotype mAb control, and the mouse ant...
a<p>Mice were treated i.p. with 100 µg of MAb at the indicated days before or after challenge with 1...
<p>Anti-H4 antibody (20 mg/ml) or the IgG control (20 mg/ml) were given once intravenously just befo...
a<p>Mice were treated i.p. with various doses of the MAb 1 dpi with 1000 LD<sub>50</sub> of the MA-Z...
Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly humanized o...
Background: Current anti-cancer therapeutic antibodies that are used in the clinic are predominantly...
<p>(A) The Kaplan-Meier survival curve. BALB/c mice (n=7 per group in two separate experiments) were...
a<p><i>p</i> value vs. controls determined from Kaplan-Meier survival plots by log-rank (Mantel-Cox)...
<p>Mice were administered mAb(s) by the i.p. route followed 18 h later by i.n. challenge with 15 LD<...
Human intravenous immunoglobulin (IVIG) is a fractionated blood product that is used for the treatme...
For each model, mice were dosed with either 1μg α-OX40 antibody or 400μg isotype control antibody ev...
<p>Indicated treatments were given i.v. twice weekly when the tumors became palpable. (<b>a</b>) Com...